Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-Human Phase I Study of TIGIT-Blocked NK510 Cells in Patients With PD-1 Refractory Advanced NSCLC

NCT06097962 is registered in ClinicalTrials.gov with Base Therapeutics (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT06097962
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06097962 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-Human Phase I Study of TIGIT-Blocked NK510 Cells in Patients With PD-1 Refractory Advanced NSCLC
Lead sponsor
Base Therapeutics (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
July 1, 2023
Completion date
July 1, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc